Guardant Health 的股价在第四季度收益低于预期后下跌 6.9%，但分析师上调了评级。 Guardant Health's stock drops 6.9% after Q4 earnings miss estimates, but gets analyst upgrades.

在报告Q4 EPS(0.90美元)低于预期、估计损失为0.15美元之后,警卫健康公司的份额下降了6.9%。 Guardant Health's shares fell 6.9% after reporting a weaker-than-expected Q4 EPS of ($0.90), missing estimates by ($0.15). 尽管下降,但若干分析家仍维持“Buy”评级,协商一致的目标从42.63美元到44.39美元不等。 Despite the decline, several analysts maintain a "Buy" rating, with consensus targets ranging from $42.63 to $44.39. 值得注意的升级包括具有“超重”评级和60美元目标的巴克莱。 Notable upgrades include Barclays with an "overweight" rating and a $60.00 target. 内部人士最近出售股票,机构投资者持有92.60%的股票。 Insiders have sold shares recently, with institutional investors holding 92.60% of the stock. 保护健康提供精确的肿瘤服务,包括血液和组织检测。 Guardant Health provides precision oncology services including blood and tissue tests.